Eli Lilly's Director, Lilly Endowment Inc, sold a total of 15,485 shares of common stock on February 20, 2025, in multiple transactions with prices ranging from $877 to $880.19. Such sales by key executives or major shareholders often indicate that the company's stock may be overvalued. Investors should remain cautious.